X

Trial Profile

A confirmatory clinical PK/PD study of RLYB116

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RLYB 116 (Primary)
Indications Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Rallybio

Most Recent Events

10 Jan 2025 According to a Rallybio Corporation media release, Cohort 1 data readout from clinical PK/PD study in the third quarter of 2025 and cohort 2 data readout from clinical PK/PD study in the fourth quarter of 2025
04 Jan 2025 New trial record
02 Dec 2024 According to a Rallybio Corporation media release, company is planning to initiate a confirmatory clinical PK/PD study of RLYB116 in the second quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com